Latest Pharma Insights
Natural Claims, Packaging Scrutinized In Beauty Lawsuits
Dr. Squatch’s proposed $9m settlement over ‘natural’ claims and Sol de Janeiro’s trade dress dispute with MCoBeauty offer two cautionary cases for beauty brands navigating product marketing and packaging risks.
HBW Insight - October 19, 2026
Dr. Squatch’s proposed $9m settlement over ‘natural’ claims and Sol de Janeiro’s trade dress dispute with MCoBeauty offer two cautionary cases for beauty brands navigating product marketing and packaging risks.
HBW Insight - October 19, 2026
Veradermics’ VDPHL01 Hits Hair Loss Endpoint Again, 12-Month Safety Is Next Test
Third positive data readout for the extended-release minoxidil positions drug for filing in male pattern hair loss, with Phase III data in female patients expected in 2027.
Scrip - October 19, 2026
Third positive data readout for the extended-release minoxidil positions drug for filing in male pattern hair loss, with Phase III data in female patients expected in 2027.
Scrip - October 19, 2026
Roche Strikes Second Deal With Hansoh, Seventh With A China-Based Partner This Year
Deal Snapshot: Roche continues its China partnering streak with seven alliances so far in 2026, paying Hansoh $400m up front and potentially more than $15bn under a deal for multiple antibody-drug conjugates.
Scrip - October 19, 2026
Deal Snapshot: Roche continues its China partnering streak with seven alliances so far in 2026, paying Hansoh $400m up front and potentially more than $15bn under a deal for multiple antibody-drug conjugates.
Scrip - October 19, 2026
AdvaMed MedTech 2026: Growth Investors Want High Unmet Need And Lower Costs, Not Hot Categories
Four growth-stage investors at the AdvaMed MedTech Conference said they avoid hot sectors in favor of devices that address high unmet need and chronic disease, citing spine, obesity and renal denervation as crowded fields.
Medtech Insight - October 19, 2026
Four growth-stage investors at the AdvaMed MedTech Conference said they avoid hot sectors in favor of devices that address high unmet need and chronic disease, citing spine, obesity and renal denervation as crowded fields.
Medtech Insight - October 19, 2026
Merck KGaA Likes The Sound Of Silence
The acquisition of Silence Therapeutics will add a Phase III-ready asset for polycythemia vera to the German drugmaker’s pipeline.
Scrip - October 19, 2026
The acquisition of Silence Therapeutics will add a Phase III-ready asset for polycythemia vera to the German drugmaker’s pipeline.
Scrip - October 19, 2026
AdvaMed Calls for Tariff Stability and Faster Device Coverage at MedTech Conference
AdvaMed CEO Scott Whitaker listed tariffs, user fees, reimbursement predictability and strengthening cybersecurity as his top policy priorities during a press conference to lead off the MedTech Conference in Boston.
Medtech Insight - October 19, 2026
AdvaMed CEO Scott Whitaker listed tariffs, user fees, reimbursement predictability and strengthening cybersecurity as his top policy priorities during a press conference to lead off the MedTech Conference in Boston.
Medtech Insight - October 19, 2026
RevMed Makes The Case For Going It Alone In Europe
Chief global commercialization officer Anthony Mancini talked to Scrip about why the company is building a commercial organization to sell Rasonque independently in Europe.
Scrip - October 19, 2026
Chief global commercialization officer Anthony Mancini talked to Scrip about why the company is building a commercial organization to sell Rasonque independently in Europe.
Scrip - October 19, 2026
Identity And Safety Guidance Is Third From US FDA On NDI Notifications
Office of Dietary Supplement Programs announces availability of “New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI” final guidance.
HBW Insight - October 19, 2026
Office of Dietary Supplement Programs announces availability of “New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI” final guidance.
HBW Insight - October 19, 2026
ESMO 2026: What Moderna, Merck, Roche, AstraZeneca And Others Need From Phase III Data
ESMO takes place in Madrid from Oct. 23-27. Late-breaking data from novel cancer vaccines to next-generation KRAS G12C inhibitors and new antibody-drug conjugates will show whether next-generation challengers can beat established standards of care. Scrip previews key readouts.
Scrip - October 19, 2026
ESMO takes place in Madrid from Oct. 23-27. Late-breaking data from novel cancer vaccines to next-generation KRAS G12C inhibitors and new antibody-drug conjugates will show whether next-generation challengers can beat established standards of care. Scrip previews key readouts.
Scrip - October 19, 2026
Nouscom Banks Another €120m To Advance Lynch Vaccine
Building on Phase Ib/II data, and having received FDA fast track Designation, Nouscom is set to initiate a registration-enabling trial for its off-the-shelf neoantigen-based vaccine.
Scrip - October 19, 2026
Building on Phase Ib/II data, and having received FDA fast track Designation, Nouscom is set to initiate a registration-enabling trial for its off-the-shelf neoantigen-based vaccine.
Scrip - October 19, 2026
Kimberly-Clark’s Kenvue Buy Clears EU Review After Agreeing To Divest European Tampon Brands
The European Commission cleared Kimberly-Clark’s $48.7bn Kenvue buyout on condition it sells its EEA tampon and feminine hygiene brands, including Kotex. The remedy follows similar feminine care divestments in Australia and Brazil.
Medtech Insight - October 19, 2026
The European Commission cleared Kimberly-Clark’s $48.7bn Kenvue buyout on condition it sells its EEA tampon and feminine hygiene brands, including Kotex. The remedy follows similar feminine care divestments in Australia and Brazil.
Medtech Insight - October 19, 2026
FDA Consumer Health Advisory: OTC Approval For First Apraclonidine 0.125% Solution In US
What's happening, why it matters and what's next at FDA. This edition explores the agency's approval of Alcon's Brytly (apraclonidine) for nonprescription sales; safety questions around prostaglandin analogues in cosmetics; and Bausch + Lomb's leadership change following scathing comments from FDA.
HBW Insight - October 19, 2026
What's happening, why it matters and what's next at FDA. This edition explores the agency's approval of Alcon's Brytly (apraclonidine) for nonprescription sales; safety questions around prostaglandin analogues in cosmetics; and Bausch + Lomb's leadership change following scathing comments from FDA.
HBW Insight - October 19, 2026
Fractyl’s Revita Clears First Pivotal Hurdle In Post-GLP-1 Weight Maintenance; De Novo Request Next
Fractyl’s Revita met the six-month co-primary endpoint in the 308-patient REMAIN-1 pivotal study, and a De Novo request is planned for late Q4, but shares closed down about 63% on the day of the data as investors weighed a class action and unproven 12-month durability.
Medtech Insight - October 19, 2026
Fractyl’s Revita met the six-month co-primary endpoint in the 308-patient REMAIN-1 pivotal study, and a De Novo request is planned for late Q4, but shares closed down about 63% on the day of the data as investors weighed a class action and unproven 12-month durability.
Medtech Insight - October 19, 2026
Medicines For Europe Urges EU States To Follow Dutch Example On Implementing UWWTD
Medicines For Europe has suggested that the Netherlands’ proposal to transpose the Urban Waste Water Treatment Directive without implementing certain controversial EPR aspects is the way forward for an industry hesitant about the current state of the legislation.
Generics Bulletin - October 19, 2026
Medicines For Europe has suggested that the Netherlands’ proposal to transpose the Urban Waste Water Treatment Directive without implementing certain controversial EPR aspects is the way forward for an industry hesitant about the current state of the legislation.
Generics Bulletin - October 19, 2026
EMA Endorsements Add Further Biosimilar Competition On Lucentis And Neulasta
The latest CHMP meeting at the EMA has seen the European agency endorse two biosimilars: Accord’s Fovlussea (ranibizumab) rival to Lucentis and CuraTeQ’s Neuzafy (filgrastim) version of Neupogen.
Generics Bulletin - October 19, 2026
The latest CHMP meeting at the EMA has seen the European agency endorse two biosimilars: Accord’s Fovlussea (ranibizumab) rival to Lucentis and CuraTeQ’s Neuzafy (filgrastim) version of Neupogen.
Generics Bulletin - October 19, 2026
MHRA’s 2030 Vision Puts Lifetime Monitoring At Center Of Medtech Plans
The UK agency confirms an AI center, early access scheme and PCCPs in a push for more adaptive regulation – but industry wants more details.
Medtech Insight - October 19, 2026
The UK agency confirms an AI center, early access scheme and PCCPs in a push for more adaptive regulation – but industry wants more details.
Medtech Insight - October 19, 2026
EY Pulse Of Medtech Industry Report Shows Record Revenues Of $650Bn In 2025; AI Remains Focus
Medtechs raised $63bn in financing in year ended June 30, up 87% YOY, and saw $650bn in 2025 revenue despite margin pressure, supply chain risk and global trade uncertainty, EY reported. AI will reshape the next decade. Medtechs should embed intelligence into products, focus on ASCs and home care.
Medtech Insight - October 19, 2026
Medtechs raised $63bn in financing in year ended June 30, up 87% YOY, and saw $650bn in 2025 revenue despite margin pressure, supply chain risk and global trade uncertainty, EY reported. AI will reshape the next decade. Medtechs should embed intelligence into products, focus on ASCs and home care.
Medtech Insight - October 19, 2026
Off-Patent, On Record: Unlocking The Value Of Biosimilars Beyond Savings With IGBA’s Ana Gaunt
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? talks to the International Generic and Biosimilar medicines Association’s secretary general Ana Gaunt to mark the start of Global Biosimilars Week, a worldwide awareness and education campaign spotlighting the importance of biosimilars.
Generics Bulletin - October 19, 2026
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? talks to the International Generic and Biosimilar medicines Association’s secretary general Ana Gaunt to mark the start of Global Biosimilars Week, a worldwide awareness and education campaign spotlighting the importance of biosimilars.
Generics Bulletin - October 19, 2026
ESMO 26 China Preview: First Results From Innovent, InSilico, Mabwell In ADCs, AI-Designed Drugs
Innovent’s EGFR/B7H3-targeting bispecific ADC, InSilico’s AI-designed pan-TEAD and Mabwell’s nectin-4–targeting ADC show strengths while seeking global-first status.
Scrip - October 19, 2026
Innovent’s EGFR/B7H3-targeting bispecific ADC, InSilico’s AI-designed pan-TEAD and Mabwell’s nectin-4–targeting ADC show strengths while seeking global-first status.
Scrip - October 19, 2026
Start at the Patient’s Chair: Why Launch Teams Should Plan Access in Reverse
Launch teams should plan the path to treatment from the patient’s chair backward, speakers from distribution, rare-disease commercialization and policy agreed. Licensing delays, payer rules and site-of-care shifts are costly to fix after approval.
In Vivo - October 19, 2026
Launch teams should plan the path to treatment from the patient’s chair backward, speakers from distribution, rare-disease commercialization and policy agreed. Licensing delays, payer rules and site-of-care shifts are costly to fix after approval.
In Vivo - October 19, 2026
Executives On The Move: Vir Biotechnology Gets A New Chief Medical Officer
Among other executive moves are two Roche departures, to Oak Hill Bio and Pharmanovia, and three Moderna departures, to Ocugen and Everest Medicines.
Scrip - October 19, 2026
Among other executive moves are two Roche departures, to Oak Hill Bio and Pharmanovia, and three Moderna departures, to Ocugen and Everest Medicines.
Scrip - October 19, 2026
Dexcom Hopes Strong CONNECT Data Will Break The CGM Reimbursement Quagmire
The CGM pioneer is proactively carving out new market positions amid a global environment that does not always see the value in diabetes tech.
Medtech Insight - October 19, 2026
The CGM pioneer is proactively carving out new market positions amid a global environment that does not always see the value in diabetes tech.
Medtech Insight - October 19, 2026
From Oncology To Cardiometabolic: Menarini’s Innovation Push Gathers Pace
Menarini CEO Elcin Barker Ergun kept Stemline intact, licensed an obesity drug and, with NewAmsterdam, secured the first obicetrapib approval. In an exclusive interview, she explains why a 140-year-old primary-care group is betting on first-in-class oncology, and what success looks like in 2030.
In Vivo - October 19, 2026
Menarini CEO Elcin Barker Ergun kept Stemline intact, licensed an obesity drug and, with NewAmsterdam, secured the first obicetrapib approval. In an exclusive interview, she explains why a 140-year-old primary-care group is betting on first-in-class oncology, and what success looks like in 2030.
In Vivo - October 19, 2026
IGBA Kicks Off Global Biosimilars Week 2026
Today marks the start of Global Biosimilars Week 2026, the latest instalment of the annual campaign from the IGBA that this year will focus on realizing the global value of biosimilars.
Generics Bulletin - October 19, 2026
Today marks the start of Global Biosimilars Week 2026, the latest instalment of the annual campaign from the IGBA that this year will focus on realizing the global value of biosimilars.
Generics Bulletin - October 19, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness.
Scrip - October 19, 2026
In this week's episode: Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness.
Scrip - October 19, 2026
Veradermics’ VDPHL01 Hits Hair Loss Endpoint Again, 12-Month Safety Is Next Test
Third positive data readout for the extended-release minoxidil positions drug for filing in male pattern hair loss, with Phase III data in female patients expected in 2027.
Scrip - October 19, 2026
Third positive data readout for the extended-release minoxidil positions drug for filing in male pattern hair loss, with Phase III data in female patients expected in 2027.
Scrip - October 19, 2026
Roche Strikes Second Deal With Hansoh, Seventh With A China-Based Partner This Year
Deal Snapshot: Roche continues its China partnering streak with seven alliances so far in 2026, paying Hansoh $400m up front and potentially more than $15bn under a deal for multiple antibody-drug conjugates.
Scrip - October 19, 2026
Deal Snapshot: Roche continues its China partnering streak with seven alliances so far in 2026, paying Hansoh $400m up front and potentially more than $15bn under a deal for multiple antibody-drug conjugates.
Scrip - October 19, 2026
Merck KGaA Likes The Sound Of Silence
The acquisition of Silence Therapeutics will add a Phase III-ready asset for polycythemia vera to the German drugmaker’s pipeline.
Scrip - October 19, 2026
The acquisition of Silence Therapeutics will add a Phase III-ready asset for polycythemia vera to the German drugmaker’s pipeline.
Scrip - October 19, 2026
RevMed Makes The Case For Going It Alone In Europe
Chief global commercialization officer Anthony Mancini talked to Scrip about why the company is building a commercial organization to sell Rasonque independently in Europe.
Scrip - October 19, 2026
Chief global commercialization officer Anthony Mancini talked to Scrip about why the company is building a commercial organization to sell Rasonque independently in Europe.
Scrip - October 19, 2026
ESMO 2026: What Moderna, Merck, Roche, AstraZeneca And Others Need From Phase III Data
ESMO takes place in Madrid from Oct. 23-27. Late-breaking data from novel cancer vaccines to next-generation KRAS G12C inhibitors and new antibody-drug conjugates will show whether next-generation challengers can beat established standards of care. Scrip previews key readouts.
Scrip - October 19, 2026
ESMO takes place in Madrid from Oct. 23-27. Late-breaking data from novel cancer vaccines to next-generation KRAS G12C inhibitors and new antibody-drug conjugates will show whether next-generation challengers can beat established standards of care. Scrip previews key readouts.
Scrip - October 19, 2026
Nouscom Banks Another €120m To Advance Lynch Vaccine
Building on Phase Ib/II data, and having received FDA fast track Designation, Nouscom is set to initiate a registration-enabling trial for its off-the-shelf neoantigen-based vaccine.
Scrip - October 19, 2026
Building on Phase Ib/II data, and having received FDA fast track Designation, Nouscom is set to initiate a registration-enabling trial for its off-the-shelf neoantigen-based vaccine.
Scrip - October 19, 2026
ESMO 26 China Preview: First Results From Innovent, InSilico, Mabwell In ADCs, AI-Designed Drugs
Innovent’s EGFR/B7H3-targeting bispecific ADC, InSilico’s AI-designed pan-TEAD and Mabwell’s nectin-4–targeting ADC show strengths while seeking global-first status.
Scrip - October 19, 2026
Innovent’s EGFR/B7H3-targeting bispecific ADC, InSilico’s AI-designed pan-TEAD and Mabwell’s nectin-4–targeting ADC show strengths while seeking global-first status.
Scrip - October 19, 2026
Executives On The Move: Vir Biotechnology Gets A New Chief Medical Officer
Among other executive moves are two Roche departures, to Oak Hill Bio and Pharmanovia, and three Moderna departures, to Ocugen and Everest Medicines.
Scrip - October 19, 2026
Among other executive moves are two Roche departures, to Oak Hill Bio and Pharmanovia, and three Moderna departures, to Ocugen and Everest Medicines.
Scrip - October 19, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness.
Scrip - October 19, 2026
In this week's episode: Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness.
Scrip - October 19, 2026
AdvaMed MedTech 2026: Growth Investors Want High Unmet Need And Lower Costs, Not Hot Categories
Four growth-stage investors at the AdvaMed MedTech Conference said they avoid hot sectors in favor of devices that address high unmet need and chronic disease, citing spine, obesity and renal denervation as crowded fields.
Medtech Insight - October 19, 2026
Four growth-stage investors at the AdvaMed MedTech Conference said they avoid hot sectors in favor of devices that address high unmet need and chronic disease, citing spine, obesity and renal denervation as crowded fields.
Medtech Insight - October 19, 2026
AdvaMed Calls for Tariff Stability and Faster Device Coverage at MedTech Conference
AdvaMed CEO Scott Whitaker listed tariffs, user fees, reimbursement predictability and strengthening cybersecurity as his top policy priorities during a press conference to lead off the MedTech Conference in Boston.
Medtech Insight - October 19, 2026
AdvaMed CEO Scott Whitaker listed tariffs, user fees, reimbursement predictability and strengthening cybersecurity as his top policy priorities during a press conference to lead off the MedTech Conference in Boston.
Medtech Insight - October 19, 2026
Kimberly-Clark’s Kenvue Buy Clears EU Review After Agreeing To Divest European Tampon Brands
The European Commission cleared Kimberly-Clark’s $48.7bn Kenvue buyout on condition it sells its EEA tampon and feminine hygiene brands, including Kotex. The remedy follows similar feminine care divestments in Australia and Brazil.
Medtech Insight - October 19, 2026
The European Commission cleared Kimberly-Clark’s $48.7bn Kenvue buyout on condition it sells its EEA tampon and feminine hygiene brands, including Kotex. The remedy follows similar feminine care divestments in Australia and Brazil.
Medtech Insight - October 19, 2026
Fractyl’s Revita Clears First Pivotal Hurdle In Post-GLP-1 Weight Maintenance; De Novo Request Next
Fractyl’s Revita met the six-month co-primary endpoint in the 308-patient REMAIN-1 pivotal study, and a De Novo request is planned for late Q4, but shares closed down about 63% on the day of the data as investors weighed a class action and unproven 12-month durability.
Medtech Insight - October 19, 2026
Fractyl’s Revita met the six-month co-primary endpoint in the 308-patient REMAIN-1 pivotal study, and a De Novo request is planned for late Q4, but shares closed down about 63% on the day of the data as investors weighed a class action and unproven 12-month durability.
Medtech Insight - October 19, 2026
MHRA’s 2030 Vision Puts Lifetime Monitoring At Center Of Medtech Plans
The UK agency confirms an AI center, early access scheme and PCCPs in a push for more adaptive regulation – but industry wants more details.
Medtech Insight - October 19, 2026
The UK agency confirms an AI center, early access scheme and PCCPs in a push for more adaptive regulation – but industry wants more details.
Medtech Insight - October 19, 2026
EY Pulse Of Medtech Industry Report Shows Record Revenues Of $650Bn In 2025; AI Remains Focus
Medtechs raised $63bn in financing in year ended June 30, up 87% YOY, and saw $650bn in 2025 revenue despite margin pressure, supply chain risk and global trade uncertainty, EY reported. AI will reshape the next decade. Medtechs should embed intelligence into products, focus on ASCs and home care.
Medtech Insight - October 19, 2026
Medtechs raised $63bn in financing in year ended June 30, up 87% YOY, and saw $650bn in 2025 revenue despite margin pressure, supply chain risk and global trade uncertainty, EY reported. AI will reshape the next decade. Medtechs should embed intelligence into products, focus on ASCs and home care.
Medtech Insight - October 19, 2026
Dexcom Hopes Strong CONNECT Data Will Break The CGM Reimbursement Quagmire
The CGM pioneer is proactively carving out new market positions amid a global environment that does not always see the value in diabetes tech.
Medtech Insight - October 19, 2026
The CGM pioneer is proactively carving out new market positions amid a global environment that does not always see the value in diabetes tech.
Medtech Insight - October 19, 2026
Natural Claims, Packaging Scrutinized In Beauty Lawsuits
Dr. Squatch’s proposed $9m settlement over ‘natural’ claims and Sol de Janeiro’s trade dress dispute with MCoBeauty offer two cautionary cases for beauty brands navigating product marketing and packaging risks.
HBW Insight - October 19, 2026
Dr. Squatch’s proposed $9m settlement over ‘natural’ claims and Sol de Janeiro’s trade dress dispute with MCoBeauty offer two cautionary cases for beauty brands navigating product marketing and packaging risks.
HBW Insight - October 19, 2026
Identity And Safety Guidance Is Third From US FDA On NDI Notifications
Office of Dietary Supplement Programs announces availability of “New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI” final guidance.
HBW Insight - October 19, 2026
Office of Dietary Supplement Programs announces availability of “New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI” final guidance.
HBW Insight - October 19, 2026
FDA Consumer Health Advisory: OTC Approval For First Apraclonidine 0.125% Solution In US
What's happening, why it matters and what's next at FDA. This edition explores the agency's approval of Alcon's Brytly (apraclonidine) for nonprescription sales; safety questions around prostaglandin analogues in cosmetics; and Bausch + Lomb's leadership change following scathing comments from FDA.
HBW Insight - October 19, 2026
What's happening, why it matters and what's next at FDA. This edition explores the agency's approval of Alcon's Brytly (apraclonidine) for nonprescription sales; safety questions around prostaglandin analogues in cosmetics; and Bausch + Lomb's leadership change following scathing comments from FDA.
HBW Insight - October 19, 2026
Medicines For Europe Urges EU States To Follow Dutch Example On Implementing UWWTD
Medicines For Europe has suggested that the Netherlands’ proposal to transpose the Urban Waste Water Treatment Directive without implementing certain controversial EPR aspects is the way forward for an industry hesitant about the current state of the legislation.
Generics Bulletin - October 19, 2026
Medicines For Europe has suggested that the Netherlands’ proposal to transpose the Urban Waste Water Treatment Directive without implementing certain controversial EPR aspects is the way forward for an industry hesitant about the current state of the legislation.
Generics Bulletin - October 19, 2026
EMA Endorsements Add Further Biosimilar Competition On Lucentis And Neulasta
The latest CHMP meeting at the EMA has seen the European agency endorse two biosimilars: Accord’s Fovlussea (ranibizumab) rival to Lucentis and CuraTeQ’s Neuzafy (filgrastim) version of Neupogen.
Generics Bulletin - October 19, 2026
The latest CHMP meeting at the EMA has seen the European agency endorse two biosimilars: Accord’s Fovlussea (ranibizumab) rival to Lucentis and CuraTeQ’s Neuzafy (filgrastim) version of Neupogen.
Generics Bulletin - October 19, 2026
Off-Patent, On Record: Unlocking The Value Of Biosimilars Beyond Savings With IGBA’s Ana Gaunt
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? talks to the International Generic and Biosimilar medicines Association’s secretary general Ana Gaunt to mark the start of Global Biosimilars Week, a worldwide awareness and education campaign spotlighting the importance of biosimilars.
Generics Bulletin - October 19, 2026
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? talks to the International Generic and Biosimilar medicines Association’s secretary general Ana Gaunt to mark the start of Global Biosimilars Week, a worldwide awareness and education campaign spotlighting the importance of biosimilars.
Generics Bulletin - October 19, 2026
IGBA Kicks Off Global Biosimilars Week 2026
Today marks the start of Global Biosimilars Week 2026, the latest instalment of the annual campaign from the IGBA that this year will focus on realizing the global value of biosimilars.
Generics Bulletin - October 19, 2026
Today marks the start of Global Biosimilars Week 2026, the latest instalment of the annual campaign from the IGBA that this year will focus on realizing the global value of biosimilars.
Generics Bulletin - October 19, 2026
Start at the Patient’s Chair: Why Launch Teams Should Plan Access in Reverse
Launch teams should plan the path to treatment from the patient’s chair backward, speakers from distribution, rare-disease commercialization and policy agreed. Licensing delays, payer rules and site-of-care shifts are costly to fix after approval.
In Vivo - October 19, 2026
Launch teams should plan the path to treatment from the patient’s chair backward, speakers from distribution, rare-disease commercialization and policy agreed. Licensing delays, payer rules and site-of-care shifts are costly to fix after approval.
In Vivo - October 19, 2026
From Oncology To Cardiometabolic: Menarini’s Innovation Push Gathers Pace
Menarini CEO Elcin Barker Ergun kept Stemline intact, licensed an obesity drug and, with NewAmsterdam, secured the first obicetrapib approval. In an exclusive interview, she explains why a 140-year-old primary-care group is betting on first-in-class oncology, and what success looks like in 2030.
In Vivo - October 19, 2026
Menarini CEO Elcin Barker Ergun kept Stemline intact, licensed an obesity drug and, with NewAmsterdam, secured the first obicetrapib approval. In an exclusive interview, she explains why a 140-year-old primary-care group is betting on first-in-class oncology, and what success looks like in 2030.
In Vivo - October 19, 2026